US20060161997A1 - Methods for producing human antibodies in SCID mice - Google Patents
Methods for producing human antibodies in SCID mice Download PDFInfo
- Publication number
- US20060161997A1 US20060161997A1 US11/370,879 US37087906A US2006161997A1 US 20060161997 A1 US20060161997 A1 US 20060161997A1 US 37087906 A US37087906 A US 37087906A US 2006161997 A1 US2006161997 A1 US 2006161997A1
- Authority
- US
- United States
- Prior art keywords
- psa
- antigen
- human
- immunization
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000011579 SCID mouse model Methods 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 title claims description 33
- 210000004443 dendritic cell Anatomy 0.000 claims abstract description 65
- 238000004519 manufacturing process Methods 0.000 claims abstract description 18
- 239000000427 antigen Substances 0.000 claims description 36
- 108091007433 antigens Proteins 0.000 claims description 34
- 102000036639 antigens Human genes 0.000 claims description 34
- 230000003053 immunization Effects 0.000 claims description 32
- 238000002649 immunization Methods 0.000 claims description 29
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 12
- 238000000338 in vitro Methods 0.000 claims description 11
- 210000005259 peripheral blood Anatomy 0.000 claims description 7
- 239000011886 peripheral blood Substances 0.000 claims description 7
- 230000009466 transformation Effects 0.000 claims description 4
- 229940124452 immunizing agent Drugs 0.000 abstract description 3
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 62
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 62
- 241000699670 Mus sp. Species 0.000 description 49
- 210000004027 cell Anatomy 0.000 description 25
- 210000000265 leukocyte Anatomy 0.000 description 18
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 17
- 206010028980 Neoplasm Diseases 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 12
- 210000000952 spleen Anatomy 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 210000001165 lymph node Anatomy 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- -1 OCT compound Chemical class 0.000 description 7
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 241000283707 Capra Species 0.000 description 6
- 206010060862 Prostate cancer Diseases 0.000 description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000003442 weekly effect Effects 0.000 description 6
- 239000012636 effector Substances 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 101150013553 CD40 gene Proteins 0.000 description 4
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 4
- 101000605534 Homo sapiens Prostate-specific antigen Proteins 0.000 description 4
- 101000592517 Homo sapiens Puromycin-sensitive aminopeptidase Proteins 0.000 description 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 3
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 3
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 3
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 3
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 230000028996 humoral immune response Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 239000004017 serum-free culture medium Substances 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 241001326189 Gyrodactylus prostae Species 0.000 description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 108010073807 IgG Receptors Proteins 0.000 description 2
- 102000009490 IgG Receptors Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000002962 histologic effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 229960000814 tetanus toxoid Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- 102100037982 Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A Human genes 0.000 description 1
- 102000039506 BAGE family Human genes 0.000 description 1
- 108091067183 BAGE family Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108010031111 EBV-encoded nuclear antigen 1 Proteins 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 102100039717 G antigen 1 Human genes 0.000 description 1
- 102000040452 GAGE family Human genes 0.000 description 1
- 108091072337 GAGE family Proteins 0.000 description 1
- 102100039554 Galectin-8 Human genes 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000886137 Homo sapiens G antigen 1 Proteins 0.000 description 1
- 101000608769 Homo sapiens Galectin-8 Proteins 0.000 description 1
- 101001014223 Homo sapiens MAPK/MAK/MRK overlapping kinase Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 108010043496 Immunoglobulin Idiotypes Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000693046 Listeria phage PSA Species 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102100031520 MAPK/MAK/MRK overlapping kinase Human genes 0.000 description 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 108010008707 Mucin-1 Proteins 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 102100030856 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 102100034640 PWWP domain-containing DNA repair factor 3A Human genes 0.000 description 1
- 108050007154 PWWP domain-containing DNA repair factor 3A Proteins 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108700042075 T-Cell Receptor Genes Proteins 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 108010034034 alpha-1,6-mannosylglycoprotein beta 1,6-N-acetylglucosaminyltransferase Proteins 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- RIIWUGSYXOBDMC-UHFFFAOYSA-N benzene-1,2-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=CC=C1N RIIWUGSYXOBDMC-UHFFFAOYSA-N 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000010231 histologic analysis Methods 0.000 description 1
- 108010071652 human kallikrein-related peptidase 3 Proteins 0.000 description 1
- 102000007579 human kallikrein-related peptidase 3 Human genes 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000013388 immunohistochemistry analysis Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- AEMBWNDIEFEPTH-UHFFFAOYSA-N n-tert-butyl-n-ethylnitrous amide Chemical compound CCN(N=O)C(C)(C)C AEMBWNDIEFEPTH-UHFFFAOYSA-N 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
- A61K39/464494—Prostate specific antigen [PSA]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/58—Prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Definitions
- the subject invention provides a novel and reproducible method for producing human monoclonal antibodies to desired antigens, e.g. prostate specific antigen.
- desired antigens e.g. prostate specific antigen.
- These monoclonal antibodies because of their human origin, should be useful therapeutic agents, e.g. for the treatment of human prostate cancer.
- Antibodies that recognize and adhere to proteins on the surface of bacteria, virus or parasites help immune system cells identify, attack and remove them from the body.
- monoclonal Ab MoAb
- Such MoAbs are generally murine Abs genetically modified to contain human constant regions (“humanized”).
- humanized human constant regions
- Fully human MoAb are potentially superior to humanized murine MoAb as therapies for human cancer because of their absence of immunogenicity in humans.
- Human B cells can be stimulated to produce Abs that recognize specific human target proteins.
- previous methods are typically very complex and yield inconsistent results. Therefore, there exists a need in the art for improved methods for producing human monoclonal antibodies.
- PSA prostate specific antigen
- the present inventors have developed an improved method for producing human antibodies in SCID mice. Specifically, it has been found that immunization of SCID mice with autologous dendritic cells, e.g., autologous peripheral blood dendritic cells that have been pulsed in vitro with a desired antigen, more preferably an antigen-antibody complex, yields high antibody titers wherein such antibodies possess the desired specificity.
- autologous dendritic cells e.g., autologous peripheral blood dendritic cells that have been pulsed in vitro with a desired antigen, more preferably an antigen-antibody complex
- the present invention provides in particular a novel immunization protocol for producing human monoclonal antibodies to prostate specific antigen (PSA).
- PSA prostate specific antigen
- FIG. 1 schematically depicts the immunization strategy of the invention.
- FIG. 2 is a flow chart summarizing the engraftment and immunization of SCIDhu PBL mice.
- FIG. 3 is a FACS analysis of peripheral blood dendritic cells cultured in serum free media.
- DC were grown in triplicate cultures, harvested on day 7, pooled and subjected to FACS analysis as described in “Materials and Methods”.
- the DC generated from PBMC used to reconstitute the SCIDhu PBL mice were 65% large, MHC class II + /CD33 + /CD40 + /CD1a lo /CD14 ⁇ cells with dendritic morphology. The remaining cells were mostly T cells and some B cells. These results are similar to those obtained from cultures generated from 8 individual PBMC donors.
- FIG. 4 is a comparison of MHC and T cell co-stimulatory surface Ag expression by DC cultures.
- DC were grown in triplicate cultures, harvested on day 7, pooled and subjected to FACS analysis as described in “Materials and Methods”. Results show MHC class II, B7.1, B7.2 and CD40 expression was significantly enhanced on DC pulsed with soluble PSA but not PSA-mIG 2a . Similar results were obtained with DC cultures generated from another donor and pulsed with Tetanus toxoid.
- FIG. 5 is a quantitation of human IgG in sera of SCIDhu PBL mice. Sera was collected on days 14 and 28. Total and PSA specific human IgG were quantitated by ELISA. Results shown are the average of 8 mice per group. Error bars represent ⁇ Std. Dev.
- A Total human IgG (mg/ml). Group H mice IgG sera concentrations ranged between 0.56 and 2.19 mg/ml IgG by day 28. IgG sera concentrations in groups F and G control mice ranged between 8 and 840 ⁇ g/ml IgG by day 28.
- B PSA specific IgG ( ⁇ g/ml).
- PSA specific IgG was quantitated using a mouse monoclonal IgG specific for human PSA as a standard. Only Group H produced PSA specific IgG. C. Percent PSA specific IgG. The relative quantity of PSA specific IgG was calculated as follows: [PSA specific IgG]/[total IgG] ⁇ 100 .
- FIG. 6 is an analysis of PSA specificity of group H sera IgG.
- the present inventors have developed a novel and reproducible method to stimulate human B cells to make Ab that adhere to desired antigens, e.g. prostate specific antigen (PSA), a protein on the surface of prostate cancer cells.
- desired antigens e.g. prostate specific antigen (PSA)
- PSA prostate specific antigen
- desired antigens e.g. prostate specific antigen (PSA)
- PSA prostate specific antigen
- specific human monoclonal antibodies to desired antigens can be cloned, which have applicability in human treatments, e.g., the treatment of prostate cancer.
- Still another non-obvious distinguishing difference of the subject methods in relation to previous methods is the inclusion of intentional EBV transformation in vivo during the unique DC/Ab-Ag complex immunization steps. Also, the present inventors have determined optimal conditions for Ag boosting SCIDhu PBL mice (using PSA as a model antigen), and high affinity antibodies to PSA using two different donors.
- FIG. 1 is a flow chart summarizing the engraftment and immunization of SCIDhu mice.
- DC dendritic cells
- SCID's were reconstituted with 10 8 female PBL's and immunized with 25 mg Ab-PSA complex.
- autologous, DC cultures were initiated.
- the DC were pulsed with 25 mg/ml Ab-PSA complex on day 6, and injected i.p. on day 7.
- the mice were boosted with 25 mg of Ab-PSA complex on days 7 and 14 and with 25 mg of soluble PSA on day 21.
- Mice immunized by this method generated PSA specific IgG sera concentrations that were comparable to those induced to Tetanus Toxoid using standard immunization methods (TT in alum).
- these results were reproduced in two separate experiments using different PBMC donors. Therefore, the present immunization protocol is reproducible and therefore should be applicable to different antigens, in particular those involved in human diseases.
- the subject method uses dendritic cells which have been pulsed in vitro with antigen or antigen-antibody complexes as immunizing agents.
- Dendritic cells are professional antigen presenting cells (APC) that initiate immune response (see 1, 2 for review).
- APC professional antigen presenting cells
- PBMC peripheral blood mononuclear cell
- human DC pulsed with weakly immunogenic, tumor associated antigens (TAA) are capable of stimulating TAA specific cytotoxic T lymphocyte (CTL) proliferation and cytotoxicity, in vitro, thus illustrating both their potency as APC and their potential utility as tumor specific vaccines (8-10).
- DC derived from PBMC and cultured with GM-CSF and IL-4 express both the high affinity IgG receptor Fc ⁇ RI (CD64) and the low affinity IgG receptor Fc ⁇ RII (CD32) at varying levels (3, 11). Both CD64 and CD32 have been shown to mediate uptake of Ag by DC (11, 12). Targeting Ag to Fc ⁇ R on human monocytes and DC via monoclonal antibody (mAb)-Ag complexes reduces the amount of Ag required for Ag specific T cell activation as much as 1000-fold (13, 14).
- mAb monoclonal antibody
- DC isolated from mouse spleen and pulsed with myoglobin were capable of stimulating a primary humoral immune response in syngeneic mice, but mouse splenic DC may have different immunostimulatory effector functions than DC derived from human peripheral blood (15).
- Follicular DC (FDC)-lymphocyte clusters isolated from human tonsil enhanced growth and Ig production by CD40 activated human B cells, in vitro (16).
- tonsillar FDC are phenotypically and morphologically distinct from peripheral blood derived DC and, therefore, are likely to have different effector functions as well (17).
- SCID mice are deficient in mature lymphocytes, Ig production and lymphocyte mediated immune responses due to defective Ig and T cell receptor gene rearrangement (18).
- SCID mice reconstituted with human peripheral blood lymphocytes SCIDhu PBL mice
- SCIDhu PBL mice can be effective models of recall antigen directed Ig production by human B cells (19, 20).
- PBMC peripheral blood mononuclear cells
- RBC renal plasma mononuclear cells
- Iscoves complete media Iscove's modified Delbucco's media (Irvine Scientific, Santa Ana, Calif.) plus sodium pyruvate, minimal essential amino acids, L-glutamine (Sigma, St. Louis, Mo.) and gentamicin (Gibco BRL, Grand Island, N.Y.)) and 10% DMSO (Sigma).
- Frozen PBMC were stored in LN 2 .
- DC were grown essentially as described by Romani et al, except that Iscove's complete was supplemented with 2% Nutridoma® HU (Boehringer Mannheim Corporation, Indianapolis, Ind.) instead of 10% fetal bovine serum.
- Nutridoma® HU Boehringer Mannheim Corporation, Indianapolis, Ind.
- Freshly isolated and thawed PBMC were purified by Histopaquel (Sigma) gradient separation, washed and plated at 5 ⁇ 10 6 cells/ml in IN2 at 37° C. for 2 hrs. Non-adherent cells were gently removed with the media, additional 37° C. IN2 was added and the cells were incubated at 37° C. for 5 additional minutes.
- Non-adherent cells were again gently removed and the residual cells were cultured in IN2 supplemented with 500 U/ml IL-4 and 800 U/ml GM-CSF (Genzyme, Inc., Cambridge, Mass.). Cultures were fed with additional cytokines on day 3.
- Human PSA specific mouse monoclonal IgG 2 a (Clone 10-P20; Fitzgerald Industries International Inc., Concord, Mass.) was complexed with >99% pure PSA (Fitzgerald Industries International) at equimolar ratios at 4° C. overnight (PSA-mIgG 2a ).
- the DC enriched cultures were pulsed with 25 ⁇ g/ml (final concentration) PSA, PSA-mIgG 2a or an equivalent volume of IN2 on day 6 and non-adherent cells were harvested on day 7.
- FITC and PE labeled monoclonal antibodies were used: anti-HLA DR, DP, DQ, anti-CD 1a, anti-CD3, anti-CD11c, anti-CD 16, anti-CD32w (Fc ⁇ RII), anti-CD33, anti-CD40, anti-CD45RO, anti-CD64 (Fc ⁇ RI), anti-CD86 (B7.2), (Pharmingen, San Diego, Calif.), anti-CD4, anti-CD 14, anti-CD80 (B7.1), PE-labeled isotype controls (Becton and Dickinson, San Jose, Calif.), anti-ABC, and FITC labeled isotype controls (Harlan Bioproducts for Science, Inc., Indianapolis, Ind.).
- PBMC peripheral blood mononuclear cells
- mice were immunized with 25 ⁇ g of PSA-mIgG 2a complex weekly, 7 ⁇ 10 6 thawed autologous PBMC on day 7 and then boosted with 25 ⁇ g PSA on day 21.
- Group G Mice were immunized with 25 ⁇ g of soluble PSA weekly and 7 ⁇ 10 6 PSA pulsed DC enriched cells on day 7.
- Group H mice were immunized with 25 ⁇ g of PSA-IgG 2a complex weekly, 7.5 ⁇ 10 6 PSA-mIgG 2a pulsed DC enriched cells on day 7 and then boosted with 25 ⁇ g PSA on day 21.
- Sera was collected on days 14 and 28. Mice were sacrificed and spleens and lymph nodes were collected on day 28.
- spleens were laterally bisected and single cells isolated from one half were analyzed by flow cytometry as described above. The remaining spleens and LN were embedded in OCT compound (Sukura Finetek, Inc., Torrance, Calif.) and then simultaneously frozen and fixed in LN 2 chilled 2-methylbutane (Sigma) for immunohistochemical staining.
- Human Ig sera concentrations were assayed by quantitative ELISAs.
- ELISAs were performed in 96 well Immulon 2′ “U” ELISA plates (Dynatech Laboratories, Inc., Chantilly, Va.).
- Human IgG and IgM ELISA plates were coated with 2 ⁇ g/ml polyclonal goat anti-human IgG or goat anti-human IgM (Southern Biotechnology Associates, Inc., Birmingham, Ala.) in bicarbonate buffer (pH 9.3) overnight.
- PSA specific IgG plates were coated with 99% pure PSA at 4 ⁇ g/ml in bicarbonate buffer.
- PSA specific IgG was quantitated using a mouse monoclonal IgG 1 specific for PSA (clone ERPR8, ICN, Costa Mesa, Calif.) as a standard. Incubations were done at RT in serially diluted duplicate wells. Binding of Ig was detected by horseradish peroxidase (HRP) conjugated polyclonal goat anti-human IgM-HRP, polyclonal goat anti-human IgG-HRP or polyclonal goat anti-mouse IgG-HRP secondary antibody (Southern Biotechnology Associates) incubation and subsequent enzymatic development of o-phenylenediamine dihydrochloride (Sigma) substrate.
- HRP horseradish peroxidase
- IgG pooled sera from four group H mice was diluted 1:15 (50 ⁇ g/ml total IgG final concentration) and 1:20 (50 ⁇ g/ml total IgG final concentration) into triplicate wells containing serially diluted concentrations of soluble PSA. Soluble PSA induced inhibition of PSA specific binding by group H sera and by an equivalent concentration of control human IgG (Zymed, Inc.) was assayed using polyclonal goat anti-human IgG-HRP, as described above. These ELISA results are contained in FIG. 6 .
- Antibody (Cat. No. 10-P2O; Fitzgerald Industries Inc.) was complexed with PSA at equimolar ratios at 4° C. over night (Ab-PSA complex) and then dialyzed to remove azide.
- Ab-PSA complex Autologous peripheral blood dendritic cells (pDC) were grown in serum free media and pulsed with either 25 ⁇ g/ml soluble PSA or Ab-PSA complex. All mice received 10 8 PBMC i.p. on day 0. Each group consisted of 8 mice. Group F mice were immunized with 25 g of Ab-PSA complex weekly and with 25 ⁇ g PSA on Day 21. Group G mice were immunized with 25 ⁇ g of soluble PSA weekly and 7 ⁇ 10 6 soluble PSA pulsed pDC on day 7.
- mice were immunized with 25 ⁇ g of Ab-PSA complex weekly, 7.5 ⁇ 10 6 Ab-PSA pulsed pDC on day 7 and then 25 ⁇ g PSA on Day 21. These results are summarized in FIG. 6 .
- B Day 28 results. Graphs, from left to right are as in A. All sera IgG concentrations are expressed as mg/ml. Error bars represent ⁇ Std. Dev.
- the immunization method described in FIG. 6 enhanced human lymphocyte engraftment in SCIDhu PBL mice.
- SCIDhu PBL mice On the average, six times more human T cells were detected per spleen and more enlarged lymph nodes (LN) were isolated from group H mice than from either control group (see Table, below).
- LN lymph nodes
- the enhanced engraftment and Ig production was not induced at the expense of enhanced xenogeneic graft versus host disease (XGVHD), as has been reported in other “enhanced” SCIDhu systems.
- XGVHD enhanced xenogeneic graft versus host disease
- mice immunized, as described in FIG. 6 were sacrificed on day 28. Spleens and LN were collected from all mice. Spleens were divided in half. One half was used to determine cell numbers and to do FACS analysis (3 mice each group). The other half of the spleens and all the isolated LN were fixed and frozen for histologic analysis. Spleen cell number and percent human T cells are shown ⁇ Std Dev. (p>0.5). *: average of 8 Mice. ⁇ : average of 3 mice.
- Histologic antibody staining data (frozen/fixed slides were stained with a-hCD3 and a-hCD19) showed that Group H mice had many more human T and B cells in enlarged peripheral LN compared to control mice. Also, spleens from group H mice had more localized B cell engraftment than control mice (data not shown).
- FIG. 5 shows relative PSA specificity of pooled sera from group H mice, control hihg and group F serum.
- open circles represent pooled group H serum, and closed circles purified hIgG.
- the open triangles represent mouse F1.1 serum.
- the data shows that group H serum binds PSA 10 times greater than equal concentrations of either control hIgG.
- Panel B shows the inhibition of group H sera specific binding by soluble PSA.
- the open circles represent pooled group H serum diluted 1:15 (120 ⁇ g/ml).
- the closed circles represent pooled group H serum diluted 1;20 (90 ⁇ g/ml).
- the open tri-angles represent purified hIgG control, (90 ⁇ g/ml).
- the data shows that pooled group H sera binding can be inhibited by soluble PSA to OD 490 values obtained by an equal concentration of control hIgG in et dose dependent manner.
- human monoclonal antibodies are useful for immunotherapy or immunoprophylaxsis, e.g., treatment or prevention of of cancer and viral infections.
- the described methodology should be useful for generating human MoAb specific to any relevant target antigen (e.g., Macrophage Inhibitory Factor, E7 antigen, CEA, HIV, etc.).
- target antigen e.g., Macrophage Inhibitory Factor, E7 antigen, CEA, HIV, etc.
- the preferred antigens will comprise those expressed by human diseases treatable by monoclonal antibodies (wherein treatment includes therapeutic and prophylactic therapy), e.g., cancers, parasitic infections and viral infections.
- diseases treatable by human monoclonal antibodies include, by way of example, cancers such as breast, brain, cervical, ovarian, prostate, bladder, pancreatic, myeloma, kidney, colorectal, nasoparingeal, endometrial, lung, liver, leukemia, lymphoma, colon, stomach, skin, among others, viral diseases, including those caused by HIV, hepatitis, papillomavirus, respiratory syncytial virus, herpes, etc., and parasitic diseases, e.g., malaria.
- cancers such as breast, brain, cervical, ovarian, prostate, bladder, pancreatic, myeloma, kidney, colorectal, nasoparingeal, endometrial, lung, liver, leukemia, lympho
- the antigen will be selected from melanocytic differentiation antigens, e.g., gp100 (Kawakami et al, J. Immunol., 154:3961-3968 (1995); Cox et al, Science, 264:716-719 (1994)), MART-1/Melan A (Kawakami et al, J. Exp. Med., 180:347-352 (1994); Castelli et al, J. Exp. Med., 181:363-368 (1995)), gp75 (TRP-1) (Wang et al, J. Exp.
- antigens of MAGE family for example, MAGE-1, 2, 3, 4, 6 and 12 (Van der Bruggen et al, Science, 254:1643-1647 (1991); Rogner et al, Genomics, 29:729-731 (1995)), antigens of BAGE family (Boel et al, Immunity, 2:167-175 (1995)), antigens of GAGE family, for example, GAGE-1, 2 (Van den Eynde et al, J. Exp.
- RAGE-1 Gaugler et al, Immunogenetics, 44:323-330 (1996)
- N-acetylglucosaminyltransferase-V Guilloux et al, J. Exp. Med., 183:1173-1183 (1996)
- p15 Robots et al, J. Immunol., 154:5944-5950 (1995)
- tumor specific mutated antigens mutated ⁇ -catenin (Robbins et al, J. Exp.
- HER2/neu Feisk et al, J. Exp. Med., 181:2109-2117 (1995)
- carcinoma associated mutated mucins for example, MUC-1 gene products (Jerome et al, J. Immunol., 151:1654-1662 (1993), Ioannides et al, J. Immunol., 151:3693-3703 (1993), Takahashi et al, J. Immunol., 153:2102-2109 (1994)); EBNA gene products of EBV, for example, EBNA-1 gene product (Rickinson et al, Cancer Surveys, 13:53-80 (1992)); E7, E6 proteins of human papillomavirus (Ressing et al, J.
- PSA prostate specific antigens
- PSMA prostate specific membrane antigen
- PCTA-1 Proc. Natl. Acad. Sci. USA, 93:7252-7257 (1996)
- idiotypic epitopes or antigens for example, immunoglobulin idiotypes or T cell receptor idiotypes (Chen et al, J. Immunol., 153:4775-4787 (1994); Syrengelas et al, Nat. Med., 2:1038-1040 (1996)).
- the antigen will preferably be administered to a SCID mouse in the form of an antigen-antibody complex as described supra.
- the antigen or more preferably antigen-antibody complex will be used for in vitro priming of autologous dendritic cells, e.g., autologous peripheral blood dendritic cells.
- the amount and duration of such in vitro priming will be that which results in an enhancement of human antibody production, when the resultant primed dendritic cells are used as immunizing agents in SCID mice.
- SCID mice will be immunized with autologous dendritic cells which have been pulsed in vitro with an antigen-antibody complex and further immunized with such antigen-antibody complex as this has been shown to confer synergistic benefits (enhance total antisera-specific antibody response and relative specific IgG antibody response).
- EBV transformation be effected during immunization.
- human antibody secreting cells will be isolated from such SCID mice and used to clone human monoclonal antibodies. This may be effected by known methods.
- Monoclonal antibodies possessing desirable properties are useful as human therapeutics and prophylactics.
- These human monoclonal antibodies will be administered by known methods, e.g., systemically or parenterally, e.g., orally, subcutaneously, intravenously, intramusculatory, topically, by infusion, to patients in need of such treatment.
- the administered dosage will be a dosage that results in therapeutic or prophylactic benefits. Generally, such dosage will range from about 0.001 to 100 mg/kg, more preferably 0.01 to 50 mg/kg, still more preferably 0.1 to 5 mg/kg body weight. Moreover, such dosage will vary dependent upon the condition of the patient, the disease condition, whether other therapies are also being effected, among other factors.
- the antibody will be administered in combination with a pharmaceutically acceptable carrier or excipient, e.g., phosphate buffered saline, optionally in combination with adjuvants that enhance humoral or CTL immunity.
- a pharmaceutically acceptable carrier or excipient e.g., phosphate buffered saline, optionally in combination with adjuvants that enhance humoral or CTL immunity.
- prostate specific antigen specific antibodies these antibodies will be used for the treatment or prevention of prostate cancer as this is a known antigen expressed during prostate cancer.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Developmental Biology & Embryology (AREA)
- Oncology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
An improved method for producing human antibodies in SCID mice is provided. The improvement includes the use of dendritic cells pulsed with antigen-antibody complexes and antigen-antibody complexes as immunizing agents.
Description
- The subject invention provides a novel and reproducible method for producing human monoclonal antibodies to desired antigens, e.g. prostate specific antigen. These monoclonal antibodies, because of their human origin, should be useful therapeutic agents, e.g. for the treatment of human prostate cancer.
- Antibodies (Ab) that recognize and adhere to proteins on the surface of bacteria, virus or parasites help immune system cells identify, attack and remove them from the body. Similarly, monoclonal Ab (MoAb) that adhere to cancer cells but not to normal cells can be an effective therapy for human cancers. Such MoAbs are generally murine Abs genetically modified to contain human constant regions (“humanized”). However, fully human MoAb are potentially superior to humanized murine MoAb as therapies for human cancer because of their absence of immunogenicity in humans. Human B cells can be stimulated to produce Abs that recognize specific human target proteins. However, previous methods are typically very complex and yield inconsistent results. Therefore, there exists a need in the art for improved methods for producing human monoclonal antibodies.
- It is an object of the invention to obviate the problems of the prior art.
- It is a specific object of the invention to provide a novel method for producing human antibodies in SCID mice.
- It is an even more specific object of the invention to provide a novel method for producing human antibodies in SCID mice wherein the immunizing protocol includes the administration of dendritic cells which have been pulsed in vitro with antigen-antibody complexes and/or antigen-antibody complexes.
- It is a more specific object of the invention to provide a novel method for producing human antibodies specific to human prostate specific antigen (PSA).
- It is an even more specific object of the invention to provide a novel method for producing human antibodies to human PSA in SCID mice wherein the immunization protocol includes the administration of dendritic cells which have been pulsed in vitro with PSA-anti-PSA antibody complexes and/or PSA-anti-PSA antibody complexes.
- It is still another object of the invention to provide a novel immunization protocol for producing human antibodies in SCID mice that includes in vivo transformation with EBV during immunization.
- As discussed in greater detail infra, by judicious experimentation, the present inventors have developed an improved method for producing human antibodies in SCID mice. Specifically, it has been found that immunization of SCID mice with autologous dendritic cells, e.g., autologous peripheral blood dendritic cells that have been pulsed in vitro with a desired antigen, more preferably an antigen-antibody complex, yields high antibody titers wherein such antibodies possess the desired specificity.
- Also, it has been found that immunization with antigen-antibody complexes yields improved results, i.e., high serum antibody titers wherein such antibodies exhibit the desired specificity.
- Still further, the present invention provides in particular a novel immunization protocol for producing human monoclonal antibodies to prostate specific antigen (PSA). These antibodies, because of their specificity and human origin, should be useful for the treatment of prostate cancer. Because of their human origin, they should possess human antibody effector functions and should elicit no immunogenicity.
-
FIG. 1 schematically depicts the immunization strategy of the invention. -
FIG. 2 is a flow chart summarizing the engraftment and immunization of SCIDhu PBL mice. -
FIG. 3 is a FACS analysis of peripheral blood dendritic cells cultured in serum free media. DC were grown in triplicate cultures, harvested on day 7, pooled and subjected to FACS analysis as described in “Materials and Methods”. The DC generated from PBMC used to reconstitute the SCIDhu PBL mice were 65% large, MHC class II+/CD33+/CD40+/CD1alo/CD14− cells with dendritic morphology. The remaining cells were mostly T cells and some B cells. These results are similar to those obtained from cultures generated from 8 individual PBMC donors. All donors generated cultures that were between 50 and 75% CD11chi/CD32+/CD33+/CD40+/CD45RO+/−ClassII+/B7.1+/B7.2+DC. DC generated from different donors were heterogeneous for CD1a, CD4, CD14, and CD64 expression (Data not shown). -
FIG. 4 is a comparison of MHC and T cell co-stimulatory surface Ag expression by DC cultures. DC were grown in triplicate cultures, harvested on day 7, pooled and subjected to FACS analysis as described in “Materials and Methods”. Results show MHC class II, B7.1, B7.2 and CD40 expression was significantly enhanced on DC pulsed with soluble PSA but not PSA-mIG2a. Similar results were obtained with DC cultures generated from another donor and pulsed with Tetanus toxoid. -
FIG. 5 is a quantitation of human IgG in sera of SCIDhu PBL mice. Sera was collected ondays day 28. IgG sera concentrations in groups F and G control mice ranged between 8 and 840 μg/ml IgG byday 28. B. PSA specific IgG (μg/ml). PSA specific IgG was quantitated using a mouse monoclonal IgG specific for human PSA as a standard. Only Group H produced PSA specific IgG. C. Percent PSA specific IgG. The relative quantity of PSA specific IgG was calculated as follows: [PSA specific IgG]/[total IgG]×100. -
FIG. 6 is an analysis of PSA specificity of group H sera IgG. A. Relative PSA specificity. Human IgG in group H sera binds PSA ten times greater than the nonspecific binding generated by group F sera with an equivalent concentration of IgG or by an equivalent concentration of purified human IgG. B. Soluble PSA competition ELISA. Soluble PSA inhibits the binding of group H sera IgG in a concentration dependent manner. - The present inventors have developed a novel and reproducible method to stimulate human B cells to make Ab that adhere to desired antigens, e.g. prostate specific antigen (PSA), a protein on the surface of prostate cancer cells. Using these methods, specific human monoclonal antibodies to desired antigens can be cloned, which have applicability in human treatments, e.g., the treatment of prostate cancer.
- The advantages of the subject invention are significant.
- In particular, these methods are advantageous for the rapid production of fully human monoclonal antibodies for immunotherapy of human diseases.
- The major distinguishing differences of the subject protocols compared to prior practices are the use of Ab-antigen (Ag) complexes and autologous dendritic cells (DC) as immunizing adjuvants.
- Still another non-obvious distinguishing difference of the subject methods in relation to previous methods is the inclusion of intentional EBV transformation in vivo during the unique DC/Ab-Ag complex immunization steps. Also, the present inventors have determined optimal conditions for Ag boosting SCIDhu PBL mice (using PSA as a model antigen), and high affinity antibodies to PSA using two different donors.
- In order to generate human anti-PSA specific IgG responses that could be immortalized we have developed a novel SCIDhu mouse immunization protocol (see
FIG. 1 ). See, also,FIG. 2 , which is a flow chart summarizing the engraftment and immunization of SCIDhu mice. Briefly, we hoped that complexing antigen to the Fc receptors of dendritic cells (DC) would increase the immunogenicity of the antigen. (However, given the inherent unpredictability with monoclonal antibody manufacture, this result was not assured.) Therefore, we pulsed dendritic cells isolated and expanded from a particular donor with PSA complexed to a mouse anti-PSA IgG2a monoclonal Ab (Ab-PSA complex). - On
day 0, SCID's were reconstituted with 108 female PBL's and immunized with 25 mg Ab-PSA complex. Simultaneously, autologous, DC cultures were initiated. The DC were pulsed with 25 mg/ml Ab-PSA complex onday 6, and injected i.p. on day 7. The mice were boosted with 25 mg of Ab-PSA complex ondays 7 and 14 and with 25 mg of soluble PSA on day 21. Mice immunized by this method generated PSA specific IgG sera concentrations that were comparable to those induced to Tetanus Toxoid using standard immunization methods (TT in alum). Moreover, these results were reproduced in two separate experiments using different PBMC donors. Therefore, the present immunization protocol is reproducible and therefore should be applicable to different antigens, in particular those involved in human diseases. - As noted, the subject method uses dendritic cells which have been pulsed in vitro with antigen or antigen-antibody complexes as immunizing agents. Dendritic cells (DC) are professional antigen presenting cells (APC) that initiate immune response (see 1, 2 for review). Recently, several methods have been developed to generate human DC from peripheral blood mononuclear cell (PBMC) derived progenitor cells), ill vitro. These different culture methods yield several DC subtypes with heterogeneous morphology, phenotype and function. However, all of these DC subtypes have been shown to be potent stimulators of naive Ag specific T cells (3-5). This is due in large part to the fact that DC express class I and II MHC and co-stimulatory cell surface molecules B7.1 and B7.2 (6, 7). In addition, human DC pulsed with weakly immunogenic, tumor associated antigens (TAA) are capable of stimulating TAA specific cytotoxic T lymphocyte (CTL) proliferation and cytotoxicity, in vitro, thus illustrating both their potency as APC and their potential utility as tumor specific vaccines (8-10).
- DC derived from PBMC and cultured with GM-CSF and IL-4 express both the high affinity IgG receptor FcγRI (CD64) and the low affinity IgG receptor FcτRII (CD32) at varying levels (3, 11). Both CD64 and CD32 have been shown to mediate uptake of Ag by DC (11, 12). Targeting Ag to FcγR on human monocytes and DC via monoclonal antibody (mAb)-Ag complexes reduces the amount of Ag required for Ag specific T cell activation as much as 1000-fold (13, 14).
- Although many recent studies have analyzed human T cell activation by DC, what is not clear is whether in vitro generated DC are capable of stimulating a primary humoral immune response. DC isolated from mouse spleen and pulsed with myoglobin were capable of stimulating a primary humoral immune response in syngeneic mice, but mouse splenic DC may have different immunostimulatory effector functions than DC derived from human peripheral blood (15). Follicular DC (FDC)-lymphocyte clusters isolated from human tonsil enhanced growth and Ig production by CD40 activated human B cells, in vitro (16). However, tonsillar FDC are phenotypically and morphologically distinct from peripheral blood derived DC and, therefore, are likely to have different effector functions as well (17).
- SCID mice are deficient in mature lymphocytes, Ig production and lymphocyte mediated immune responses due to defective Ig and T cell receptor gene rearrangement (18). SCID mice reconstituted with human peripheral blood lymphocytes (SCIDhu PBL mice) can be effective models of recall antigen directed Ig production by human B cells (19, 20). However, it is very difficult to stimulate neo-Ag, self-Ag or TAA specific primary immune response and IgG production in SCIDhu PBL mice (21).
- In this study we characterized the phenotype of DC generated from PBMC in low protein, serum free media. We then assessed the ability of serum free cultured DC to stimulate a prostate specific antigen (PSA) specific, primary humoral immune response by SCIDhu PBL mice. We showed that DC pulsed with PSA complexed to a mouse IgG2a specific for human PSA (PSA-mIgG2a) can induce PSA specific human IgG production in SCIDhu PBL mice. SCIDhu PBL mice immunized with soluble PSA pulsed DC did not produce PSA specific IgG. These results suggest that the mechanism by which DC acquired Ag altered DC expression and immunostimulating effector functions. Different Ag acquisition mechanisms yield different co-stimulating molecule surface expression and subsequent immunostimulatory effector functions by DC.
- The following materials and methods were used.
- DC Generation in Serum Free Cultures
- PBMC were obtained from healthy donors by leukophoresis or by venapuncture into heparinized tubes. RBC were removed from residual PBMC by hypotonic lysis in Gey's lysis buffer prior to freezing in 50% human serum, 40% Iscoves complete media (Iscove's modified Delbucco's media (Irvine Scientific, Santa Ana, Calif.) plus sodium pyruvate, minimal essential amino acids, L-glutamine (Sigma, St. Louis, Mo.) and gentamicin (Gibco BRL, Grand Island, N.Y.)) and 10% DMSO (Sigma). Frozen PBMC were stored in LN2. DC were grown essentially as described by Romani et al, except that Iscove's complete was supplemented with 2% Nutridoma® HU (Boehringer Mannheim Corporation, Indianapolis, Ind.) instead of 10% fetal bovine serum. Freshly isolated and thawed PBMC were purified by Histopaquel (Sigma) gradient separation, washed and plated at 5×106 cells/ml in IN2 at 37° C. for 2 hrs. Non-adherent cells were gently removed with the media, additional 37° C. IN2 was added and the cells were incubated at 37° C. for 5 additional minutes. Non-adherent cells were again gently removed and the residual cells were cultured in IN2 supplemented with 500 U/ml IL-4 and 800 U/ml GM-CSF (Genzyme, Inc., Cambridge, Mass.). Cultures were fed with additional cytokines on
day 3. Human PSA specific mouse monoclonal IgG2a (Clone 10-P20; Fitzgerald Industries International Inc., Concord, Mass.) was complexed with >99% pure PSA (Fitzgerald Industries International) at equimolar ratios at 4° C. overnight (PSA-mIgG2a). The DC enriched cultures were pulsed with 25 μg/ml (final concentration) PSA, PSA-mIgG2a or an equivalent volume of IN2 onday 6 and non-adherent cells were harvested on day 7. - Flow Cytometric Analysis
- The following FITC and PE labeled monoclonal antibodies (mAb) were used: anti-HLA DR, DP, DQ, anti-CD 1a, anti-CD3, anti-CD11c,
anti-CD 16, anti-CD32w (FcγRII), anti-CD33, anti-CD40, anti-CD45RO, anti-CD64 (FcγRI), anti-CD86 (B7.2), (Pharmingen, San Diego, Calif.), anti-CD4, anti-CD 14, anti-CD80 (B7.1), PE-labeled isotype controls (Becton and Dickinson, San Jose, Calif.), anti-ABC, and FITC labeled isotype controls (Harlan Bioproducts for Science, Inc., Indianapolis, Ind.). Day 7 DC enriched cultures and single cell isolates from SCIDhu PBL mouse tissues were washed and resuspended in 4° C. FACS buffer (1% BSA, 1×PBS, 0.1% Na Azide and 40 μg/ml human IgG) at 1×106 cells/ml. The cells were then aliquoted and stained for 45 minutes with mAb diluted to the manufacturers' recommended concentration. The cells were washed twice in FACS buffer and data was acquired on a FACScan® (Becton Dickinson). Data was analyzed usingLysis 1® ((Becton Dickinson) or F cap List® (Soft FlowHungary, Inc., Pecs, Hungary) software. Specific reactivity data shown as ΔMFI is calculated as follows: MFI of FITC or PE labeled specific mAb—MFI of isotype and fluorochrome matched mAb control. These results are contained inFIGS. 3 and 4 . - SCID Mouse Engraftment and Immunization
- PBMC were obtained from healthy female donors by leukophoresis. RBC were removed by hypotonic lysis in Gey's lysis solution. Residual PBMC were frozen and stored as described above. Four to six week old male Fox Chase ICR SCID™ mice (Taconic, Germantown, N.Y.) were housed, fed and handled according to established protocols for immunodeficient strains. Mice were engrafted with 108 PBMC, i.p., on
day 0. Autologous DC cultures were initiated onday 0 as described above. Group F mice were immunized with 25 μg of PSA-mIgG2a complex weekly, 7×106 thawed autologous PBMC on day 7 and then boosted with 25 μg PSA on day 21. Group G Mice were immunized with 25 μg of soluble PSA weekly and 7×106 PSA pulsed DC enriched cells on day 7. Group H mice were immunized with 25 μg of PSA-IgG2a complex weekly, 7.5×106 PSA-mIgG2a pulsed DC enriched cells on day 7 and then boosted with 25 μg PSA on day 21. Sera was collected ondays day 28. Some spleens were laterally bisected and single cells isolated from one half were analyzed by flow cytometry as described above. The remaining spleens and LN were embedded in OCT compound (Sukura Finetek, Inc., Torrance, Calif.) and then simultaneously frozen and fixed in LN2 chilled 2-methylbutane (Sigma) for immunohistochemical staining. - ELISAs
- Human Ig sera concentrations were assayed by quantitative ELISAs. ELISAs were performed in 96
well Immulon 2′ “U” ELISA plates (Dynatech Laboratories, Inc., Chantilly, Va.). Human IgG and IgM ELISA plates were coated with 2 μg/ml polyclonal goat anti-human IgG or goat anti-human IgM (Southern Biotechnology Associates, Inc., Birmingham, Ala.) in bicarbonate buffer (pH 9.3) overnight. PSA specific IgG plates were coated with 99% pure PSA at 4 μg/ml in bicarbonate buffer. PSA specific IgG was quantitated using a mouse monoclonal IgG1 specific for PSA (clone ERPR8, ICN, Costa Mesa, Calif.) as a standard. Incubations were done at RT in serially diluted duplicate wells. Binding of Ig was detected by horseradish peroxidase (HRP) conjugated polyclonal goat anti-human IgM-HRP, polyclonal goat anti-human IgG-HRP or polyclonal goat anti-mouse IgG-HRP secondary antibody (Southern Biotechnology Associates) incubation and subsequent enzymatic development of o-phenylenediamine dihydrochloride (Sigma) substrate. Reactions were quenched with 4N H2SO4 and the plates were read on a ELISA plate reader at OD490. The concentration of human Ig in SCIDhu PBL sera was quantitated by comparison of SCIDhu PBL serum OD490 values with serially diluted standard curves. These results are contained inFIG. 5 . - To confirm the PSA binding specificity of group H sera IgG pooled sera from four group H mice was diluted 1:15 (50 μg/ml total IgG final concentration) and 1:20 (50 μg/ml total IgG final concentration) into triplicate wells containing serially diluted concentrations of soluble PSA. Soluble PSA induced inhibition of PSA specific binding by group H sera and by an equivalent concentration of control human IgG (Zymed, Inc.) was assayed using polyclonal goat anti-human IgG-HRP, as described above. These ELISA results are contained in
FIG. 6 . - Immunohistochemistry Analysis
- Histologic and human lymphocyte specific antibody (CD3 and CD 19) staining of frozen and fixed SCIDhu PBL mouse tissues was contracted to BioPharMaceutical Support Services (Pharmingen).
- Immunoblot Analysis
- These experiments are ongoing.
- Human IgG Production in DC/Ab-PSA Complex Immunized
- SCIDhu PBL Mice Mouse Monoclonal IgG.
- Antibody (Cat. No. 10-P2O; Fitzgerald Industries Inc.) was complexed with PSA at equimolar ratios at 4° C. over night (Ab-PSA complex) and then dialyzed to remove azide. Autologous peripheral blood dendritic cells (pDC) were grown in serum free media and pulsed with either 25 μg/ml soluble PSA or Ab-PSA complex. All mice received 108 PBMC i.p. on
day 0. Each group consisted of 8 mice. Group F mice were immunized with 25 g of Ab-PSA complex weekly and with 25 μg PSA on Day 21. Group G mice were immunized with 25 μg of soluble PSA weekly and 7×106 soluble PSA pulsed pDC on day 7. Group H mice were immunized with 25 μg of Ab-PSA complex weekly, 7.5×106 Ab-PSA pulsed pDC on day 7 and then 25 μg PSA on Day 21. These results are summarized inFIG. 6 . TheDay 14 results, (A) Graphs, from left to right are as follows: Average PSA specific IgG; PSA specific IgG for individual mice; Average total human IgG; Average of percent specific IgG (specific IgG/total IgG×100); percent specific IgG for individual mice.B. Day 28 results. Graphs, from left to right are as in A. All sera IgG concentrations are expressed as mg/ml. Error bars represent ±Std. Dev. - The immunization method described in
FIG. 6 enhanced human lymphocyte engraftment in SCIDhu PBL mice. On the average, six times more human T cells were detected per spleen and more enlarged lymph nodes (LN) were isolated from group H mice than from either control group (see Table, below). Importantly, the enhanced engraftment and Ig production was not induced at the expense of enhanced xenogeneic graft versus host disease (XGVHD), as has been reported in other “enhanced” SCIDhu systems.TABLE Summary of Engraftment Total Spleen % hCD3+ % hCD19+ #Mice w. Group Cells Number* Cells{circumflex over ( )} Cells{circumflex over ( )} LN/group F 1.69 ± 0.26 × 108 2.30 ± 0.67 <2% 2/8 G 1.58 ± 0.32 × 108 2.93 ± 0.34 <2% 4/8 H 3.04 ± 0.60 × 108 8.93 ± 4.32 <2% 7/8 - Mice immunized, as described in
FIG. 6 , were sacrificed onday 28. Spleens and LN were collected from all mice. Spleens were divided in half. One half was used to determine cell numbers and to do FACS analysis (3 mice each group). The other half of the spleens and all the isolated LN were fixed and frozen for histologic analysis. Spleen cell number and percent human T cells are shown ±Std Dev. (p>0.5). *: average of 8 Mice.ˆ: average of 3 mice. - Histologic antibody staining data (frozen/fixed slides were stained with a-hCD3 and a-hCD19) showed that Group H mice had many more human T and B cells in enlarged peripheral LN compared to control mice. Also, spleens from group H mice had more localized B cell engraftment than control mice (data not shown).
- The specificity of the PSA IgG response by group H mice was confirmed I by comparison with non-responding Group F sera, control human IgG and by competition of sera binding by soluble PSA.
- Specificity of Antibody Responses Obtained in Ab-PSA/pDC Immunized SCIDhu PBC Mice.
- In this Example, the relative PSA specificity of pooled sera from group H mice, control hIgG and group F serum is measured and was shown in
FIG. 5 . -
FIG. 5 shows relative PSA specificity of pooled sera from group H mice, control hihg and group F serum. In this Figure, open circles represent pooled group H serum, and closed circles purified hIgG. The open triangles represent mouse F1.1 serum. The data shows that group H serum bindsPSA 10 times greater than equal concentrations of either control hIgG. Panel B shows the inhibition of group H sera specific binding by soluble PSA. The open circles represent pooled group H serum diluted 1:15 (120 μg/ml). The closed circles represent pooled group H serum diluted 1;20 (90 μg/ml). The open tri-angles represent purified hIgG control, (90 μg/ml). The data shows that pooled group H sera binding can be inhibited by soluble PSA to OD490 values obtained by an equal concentration of control hIgG in et dose dependent manner. - Therefore, these results demonstrate that DC pulsed with antigen-antibody complexes induced PSA specific Ab responses in SCIDhu PBL mice better than previous immunization protocols. Moreover, the results demonstrate that when such pulsed DC are administered in combination with Ab-antigen complexes, that significant enhancement of total specific (>35 fold) and relative specific (>10-fold) PSA IgG responses in SCIDhu PBL mice is obtained (compared to either immunization strategy performed separately). Also, this novel immunization strategy enhanced human lymphocyte engraftment without enhancing XGVHD as in other “enhanced” SCIDhu systems. Moreover, this method was reproducible in three separate experiments using different PBMC donors.
- This approach and the technology developed around it is significant as it enables rapid, reproducible production of clinically superior products (human monoclonal antibodies) compared to antibodies based on rodent antibodies). These human monoclonal antibodies are useful for immunotherapy or immunoprophylaxsis, e.g., treatment or prevention of of cancer and viral infections.
- The described methodology should be useful for generating human MoAb specific to any relevant target antigen (e.g., Macrophage Inhibitory Factor, E7 antigen, CEA, HIV, etc.). However, being a biological system, it is impossible to predict with absolute certainty the extent of variation of the conditions or parameters that will provide optimal results for different antigens, e.g., the exact number of cells or the exact quantity of Ab-PSA complex that results in optimal antibody production or specificity. However, this can be determined by one of ordinary skill using routine optimization.
- The preferred antigens will comprise those expressed by human diseases treatable by monoclonal antibodies (wherein treatment includes therapeutic and prophylactic therapy), e.g., cancers, parasitic infections and viral infections. Examples of diseases treatable by human monoclonal antibodies include, by way of example, cancers such as breast, brain, cervical, ovarian, prostate, bladder, pancreatic, myeloma, kidney, colorectal, nasoparingeal, endometrial, lung, liver, leukemia, lymphoma, colon, stomach, skin, among others, viral diseases, including those caused by HIV, hepatitis, papillomavirus, respiratory syncytial virus, herpes, etc., and parasitic diseases, e.g., malaria.
- In the preferred embodiments, the antigen will be selected from melanocytic differentiation antigens, e.g., gp100 (Kawakami et al, J. Immunol., 154:3961-3968 (1995); Cox et al, Science, 264:716-719 (1994)), MART-1/Melan A (Kawakami et al, J. Exp. Med., 180:347-352 (1994); Castelli et al, J. Exp. Med., 181:363-368 (1995)), gp75 (TRP-1) (Wang et al, J. Exp. Med., 186:1131-1140 (1996)), and Tyrosinase (Wolfel et al, Eur. J. Immunol., 24:759-764 (1994); Topalian et al, J. Exp. Med., 183:1965-1971 (1996)); melanoma proteoglycan (Hellstrom et al, J. Immunol., 130:1467-1472 (1983); Ross et al, Arch. Biochem Biophys., 225:370-383 (1983)); tumor-specific, widely shared antigens, e.g., antigens of MAGE family, for example, MAGE-1, 2, 3, 4, 6 and 12 (Van der Bruggen et al, Science, 254:1643-1647 (1991); Rogner et al, Genomics, 29:729-731 (1995)), antigens of BAGE family (Boel et al, Immunity, 2:167-175 (1995)), antigens of GAGE family, for example, GAGE-1, 2 (Van den Eynde et al, J. Exp. Med., 182:689-698 (1995)), antigens of RAGE family, for example, RAGE-1 (Gaugler et al, Immunogenetics, 44:323-330 (1996)), N-acetylglucosaminyltransferase-V (Guilloux et al, J. Exp. Med., 183:1173-1183 (1996)), and p15 (Robbins et al, J. Immunol., 154:5944-5950 (1995)); tumor specific mutated antigens; mutated β-catenin (Robbins et al, J. Exp. Med., 183:1185-1192 (1996)), mutated MUM-1 (Coulie et al, Proc. Natl. Acad. Sci. USA, 92:7976-7980 (1995)), and mutated cyclin dependent kinases-4 (CDK4) (Wolfel et al, Science, 269:1281-1284 (1995)); mutated oncogene products: p21 ras (Fossum et al, Int. J. Cancer, 56:40-45 (1994)), BCR-abl (Bocchia et al, Blood, 85:2680-2684 (1995)), p53 (Theobald et al, Proc. Natl. Acad. Sci. USA, 92:11993-11997 (1995)), and p185 (HER2/neu (Fisk et al, J. Exp. Med., 181:2109-2117 (1995)); Peoples et al, Proc. Natl. Acad. Sci. USA, 92:432-436 (1995)); mutated epidermal growth factor receptor (EGFR) (Fugimoto et al, Eur. J. Gynecol. Oncol., 16:40-47 (19965)); Harris et al, Breast Cancer Res. Treat, 29:1-2 (1994)); carcinoembryonic antigens (CEA) (Kwong et al, J. Natl. Cancer Inst., 85:982-990 (1995)); carcinoma associated mutated mucins, for example, MUC-1 gene products (Jerome et al, J. Immunol., 151:1654-1662 (1993), Ioannides et al, J. Immunol., 151:3693-3703 (1993), Takahashi et al, J. Immunol., 153:2102-2109 (1994)); EBNA gene products of EBV, for example, EBNA-1 gene product (Rickinson et al, Cancer Surveys, 13:53-80 (1992)); E7, E6 proteins of human papillomavirus (Ressing et al, J. Immunol., 154:5934-5943 (1995)); prostate specific antigens (PSA) (Xue et al, The Prostate, 30:70-78 (1997)); prostate specific membrane antigen (PSMA) (Israeli et al, Cancer Res., 54:1807-1811 (1994)); PCTA-1 (Sue et al, Proc. Natl. Acad. Sci. USA, 93:7252-7257 (1996)); idiotypic epitopes or antigens, for example, immunoglobulin idiotypes or T cell receptor idiotypes (Chen et al, J. Immunol., 153:4775-4787 (1994); Syrengelas et al, Nat. Med., 2:1038-1040 (1996)).
- The antigen will preferably be administered to a SCID mouse in the form of an antigen-antibody complex as described supra. Also, as described supra, the antigen or more preferably antigen-antibody complex will be used for in vitro priming of autologous dendritic cells, e.g., autologous peripheral blood dendritic cells. The amount and duration of such in vitro priming will be that which results in an enhancement of human antibody production, when the resultant primed dendritic cells are used as immunizing agents in SCID mice. As disclosed, preferably SCID mice will be immunized with autologous dendritic cells which have been pulsed in vitro with an antigen-antibody complex and further immunized with such antigen-antibody complex as this has been shown to confer synergistic benefits (enhance total antisera-specific antibody response and relative specific IgG antibody response).
- Also, it is desirable that EBV transformation be effected during immunization. After immunization, human antibody secreting cells will be isolated from such SCID mice and used to clone human monoclonal antibodies. This may be effected by known methods.
- Monoclonal antibodies possessing desirable properties (minimum antigen binding affinity and avidity) obtained by such methods are useful as human therapeutics and prophylactics. These human monoclonal antibodies will be administered by known methods, e.g., systemically or parenterally, e.g., orally, subcutaneously, intravenously, intramusculatory, topically, by infusion, to patients in need of such treatment.
- The administered dosage will be a dosage that results in therapeutic or prophylactic benefits. Generally, such dosage will range from about 0.001 to 100 mg/kg, more preferably 0.01 to 50 mg/kg, still more preferably 0.1 to 5 mg/kg body weight. Moreover, such dosage will vary dependent upon the condition of the patient, the disease condition, whether other therapies are also being effected, among other factors.
- Typically, the antibody will be administered in combination with a pharmaceutically acceptable carrier or excipient, e.g., phosphate buffered saline, optionally in combination with adjuvants that enhance humoral or CTL immunity.
- In the case of prostate specific antigen specific antibodies, these antibodies will be used for the treatment or prevention of prostate cancer as this is a known antigen expressed during prostate cancer.
Claims (13)
1. A method for producing human antibodies in SCID mice which comprises immunizing SCID mice with dendritic cells which have been contacted (pulsed) in vitro with an antigen-antibody complex.
2. The method of claim 1 , wherein the antigen is prostrate specific antigen.
3. The method of claim 2 , wherein the antibody is a mouse IgG2a antibody.
4. The method of claim 1 , wherein the dendritic cells comprise autologous peripheral blood dendritic cells.
5. The method of claim 1 , which includes EBV transformation during the immunization step.
6. The method of claim 1 , wherein the antibody is anti-PSA IgG2, monoclonal antibody and the antigen is PSA.
7. The method of claim 1 , wherein said SCID mice are immunized with antigen-antibody complex prior to a immunization with dendritic which have been contacted (pulsed) with antigen-antibody complex.
8. The method of claim 1 , wherein the second immunization is effected about 1 to 15 days after the first.
9. The method of claim 8 , wherein said second immunization is effected about 7 days after the first immunization.
10. The method of claim 7 , which further includes at least one additional immunization (“boosting”) wherein SCID mice is administered antigen or antigen-antibody complex.
11. The method of claim 10 , wherein a boosting step is effected about a week after the first immunization.
12. The method of claim 11 , wherein another boosting step is effected about two weeks after the first immunization.
13. The method of claim 12 , wherein another boosting step is effected about three weeks after the first immunization.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/370,879 US20060161997A1 (en) | 1997-09-08 | 2006-03-09 | Methods for producing human antibodies in SCID mice |
US12/046,243 US20080282363A1 (en) | 1997-09-08 | 2008-03-11 | Methods for producing human antibodies in scid mice |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5783197P | 1997-09-08 | 1997-09-08 | |
US14947998A | 1998-09-08 | 1998-09-08 | |
US09/798,525 US7118924B2 (en) | 1997-09-08 | 2001-02-21 | Method for producing human antibodies in SCID mice which uses dendritic cells pulsed with antigen-antibody complexes and antigen-antibody complexes as immunizing agents |
US11/370,879 US20060161997A1 (en) | 1997-09-08 | 2006-03-09 | Methods for producing human antibodies in SCID mice |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/798,525 Continuation US7118924B2 (en) | 1997-09-08 | 2001-02-21 | Method for producing human antibodies in SCID mice which uses dendritic cells pulsed with antigen-antibody complexes and antigen-antibody complexes as immunizing agents |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/046,243 Continuation US20080282363A1 (en) | 1997-09-08 | 2008-03-11 | Methods for producing human antibodies in scid mice |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060161997A1 true US20060161997A1 (en) | 2006-07-20 |
Family
ID=22012997
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/798,525 Expired - Fee Related US7118924B2 (en) | 1997-09-08 | 2001-02-21 | Method for producing human antibodies in SCID mice which uses dendritic cells pulsed with antigen-antibody complexes and antigen-antibody complexes as immunizing agents |
US11/370,879 Abandoned US20060161997A1 (en) | 1997-09-08 | 2006-03-09 | Methods for producing human antibodies in SCID mice |
US12/046,243 Abandoned US20080282363A1 (en) | 1997-09-08 | 2008-03-11 | Methods for producing human antibodies in scid mice |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/798,525 Expired - Fee Related US7118924B2 (en) | 1997-09-08 | 2001-02-21 | Method for producing human antibodies in SCID mice which uses dendritic cells pulsed with antigen-antibody complexes and antigen-antibody complexes as immunizing agents |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/046,243 Abandoned US20080282363A1 (en) | 1997-09-08 | 2008-03-11 | Methods for producing human antibodies in scid mice |
Country Status (3)
Country | Link |
---|---|
US (3) | US7118924B2 (en) |
AU (1) | AU9374198A (en) |
WO (1) | WO1999012553A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999012553A1 (en) * | 1997-09-08 | 1999-03-18 | Idec Pharmaceuticals Corporation | Methods for producing human antibodies in scid mice using dendritic cells |
WO2000051980A1 (en) | 1999-03-05 | 2000-09-08 | The Procter & Gamble Company | C16 unsaturated fp-selective prostaglandins analogs |
DE10007771A1 (en) * | 2000-02-14 | 2001-08-23 | Kleine & Steube Entoxin Gmbh | Immunomodulatory compositions, processes for their preparation and their use |
US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
US20050208627A1 (en) * | 2003-09-18 | 2005-09-22 | Bowdish Katherine S | Elicitation of antibodies to self peptides in mice by immunization with dendritic cells |
US20070054378A1 (en) * | 2003-09-18 | 2007-03-08 | Alexion Pharmaceuticals, Inc. | Elicitation of antibodies to self peptides in mice by immunization with dendritic cells |
EP2422618A1 (en) | 2010-08-27 | 2012-02-29 | Technologie Integrale Ltd. | Animal model for the evaluation of the efficacy of an HIV vaccine |
WO2012139069A2 (en) * | 2011-04-07 | 2012-10-11 | Neotope Biosciences Limited | Compositions and methods for treating diseases of protein aggregation involving ic3b deposition |
DK3231814T3 (en) | 2016-04-14 | 2020-05-11 | Biogenes Gmbh | PROCEDURE FOR MANUFACTURING ANTIGEN-SPECIFIC B CELLS AND THEIR USE FOR MANUFACTURE OF HYBRIDOMA CELLS AND MONOCLONAL ANTIBODIES |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5663481A (en) * | 1993-08-06 | 1997-09-02 | Mount Sinai Hospital Corporation | Animal model of the human immune system |
US5672480A (en) * | 1993-12-29 | 1997-09-30 | Abbott Laboratories | Immunoassays for prostate specific antigen |
US5681729A (en) * | 1991-10-30 | 1997-10-28 | Idemitsu Kosan Company Limited | Methods for producing human lymphocytes and human monoclonal antibodies, and human monoclonal antibodies produced thereby |
US5939068A (en) * | 1995-06-07 | 1999-08-17 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
US6432653B1 (en) * | 1989-06-29 | 2002-08-13 | Aventis Pharmaceuticals Inc. | Device and process for cell capture and recovery |
US6497876B1 (en) * | 1996-07-10 | 2002-12-24 | Immunex Corp. | Method of stimulating an immune response with activated dendritic cells |
US7118924B2 (en) * | 1997-09-08 | 2006-10-10 | Biogen Idec Inc. | Method for producing human antibodies in SCID mice which uses dendritic cells pulsed with antigen-antibody complexes and antigen-antibody complexes as immunizing agents |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0563485A1 (en) * | 1992-03-30 | 1993-10-06 | Schering-Plough | In vitro generation of human dendritic cells and uses thereof |
-
1998
- 1998-09-08 WO PCT/US1998/018161 patent/WO1999012553A1/en active Application Filing
- 1998-09-08 AU AU93741/98A patent/AU9374198A/en not_active Abandoned
-
2001
- 2001-02-21 US US09/798,525 patent/US7118924B2/en not_active Expired - Fee Related
-
2006
- 2006-03-09 US US11/370,879 patent/US20060161997A1/en not_active Abandoned
-
2008
- 2008-03-11 US US12/046,243 patent/US20080282363A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6432653B1 (en) * | 1989-06-29 | 2002-08-13 | Aventis Pharmaceuticals Inc. | Device and process for cell capture and recovery |
US5681729A (en) * | 1991-10-30 | 1997-10-28 | Idemitsu Kosan Company Limited | Methods for producing human lymphocytes and human monoclonal antibodies, and human monoclonal antibodies produced thereby |
US5663481A (en) * | 1993-08-06 | 1997-09-02 | Mount Sinai Hospital Corporation | Animal model of the human immune system |
US5672480A (en) * | 1993-12-29 | 1997-09-30 | Abbott Laboratories | Immunoassays for prostate specific antigen |
US5939068A (en) * | 1995-06-07 | 1999-08-17 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
US6497876B1 (en) * | 1996-07-10 | 2002-12-24 | Immunex Corp. | Method of stimulating an immune response with activated dendritic cells |
US7118924B2 (en) * | 1997-09-08 | 2006-10-10 | Biogen Idec Inc. | Method for producing human antibodies in SCID mice which uses dendritic cells pulsed with antigen-antibody complexes and antigen-antibody complexes as immunizing agents |
Also Published As
Publication number | Publication date |
---|---|
US20020044930A1 (en) | 2002-04-18 |
US20080282363A1 (en) | 2008-11-13 |
AU9374198A (en) | 1999-03-29 |
WO1999012553A1 (en) | 1999-03-18 |
US7118924B2 (en) | 2006-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080282363A1 (en) | Methods for producing human antibodies in scid mice | |
US6689355B2 (en) | Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells | |
US8277806B2 (en) | Use of trifunctional bispecific and trispecific antibodies for the treatment of malignant ascites | |
US8012470B2 (en) | Method for ex vivo immunization using heterologous intact bispecific and/or trispecific antibodies | |
US8444974B2 (en) | Use of antibodies for the vaccination against cancer | |
AU2001267780A1 (en) | Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells | |
US8642276B2 (en) | Method for the production of an immunostimulating mucin (MUC1) | |
JP2003519096A (en) | Therapeutic antibodies to MUC-1 antigen and methods of using the same | |
JPH11509558A (en) | Method and composition for reconstituting an antigen containing multiple epitopes to elicit an immune response | |
WO2011104565A1 (en) | Camelid antibodies for use in compositions and methods for the treatment of cancer | |
Signorino et al. | Contribution of dendritic cells FcγRI and FcγRIII to cross-presentation of tumor cells opsonized with the anti-MHC class I monoclonal antibodies | |
Sivolapenko et al. | Enhanced in vivo immunogenicity induced by an antibody to the IL‐4 receptor‐associated gp200‐MR6 molecule | |
WO2024081933A1 (en) | Methods and compositions for improving response to immunotherapy | |
US20040265318A1 (en) | Use of antibodies for the vaccination against cancer | |
US20050271649A1 (en) | Therapeutic adjuvant | |
MXPA98009586A (en) | Method and composition for the reconformation of multi-peptide antigens to start an animal response |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |